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Abstract 
 Acute Mountain Sickness (AMS) and its related illnesses, high altitude cerebral edema 
(HACE), and high altitude pulmonary edema (HAPE), affect many residents of lower 
elevations that travel to high altitude for pleasure or profession. This systematic review and 
meta-analysis aimed to assess the potential relationship between sex and incidence of AMS, 
hypothesizing that females will have a lesser incidence due to the respiratory stimulant 
effects of female sex hormone progesterone. Odds ratios were compiled into a forest plot and 
a summary estimate was calculated. Contrary to the hypothesis, females were found to be 
1.48 times more likely to experience AMS symptoms compared to males (p<0.0001). It is 
concluded that there is an association between sex, specifically female sex, and incidence of 
AMS. Further research is suggested in assessing the relationship between sex and severity of 
AMS, as well as the relationship between female and male sex hormones and AMS, while 
taking into consideration specific hormone levels for each subject. 
Introduction  
Humans are equipped with a series of physiologic responses to cope with the hypoxic 
environment that exists at altitude. Decreased barometric pressure at altitude (roughly 70% 
of sea-level value at 3000m12) results in decreased partial pressure of oxygen (PO2) in 
inspired air. Consequently, PO2 is lowered at all steps of oxygen transport in the body. 
Peripheral chemoreceptors in the aortic and carotid bodies detect a decrease in arterial PO2, 
and the hypoxic ventilatory response (HVR) is initiated. To increase arterial PO2, and thus, 
the oxygen available for tissues, ventilation increases at the expense of carbon dioxide (CO2). 
This increase in CO2 removal, combined with the bicarbonate store that exists as a buffer in 
tissues, results in alkalosis, or a more basic blood pH. The kidneys respond by excreting 
additional bicarbonate in the urine1.  
The specific causes and physiologic mechanisms of AMS are still unclear. One 
potential mechanism involves a failure or delay of HVR, which could result in a buildup of 
CO2 relative to O2, and an overall acidosis (decreased blood pH). Increased partial pressure of 
CO2 (PCO2) may increase cerebral blood flow, and therefore, intracranial pressure1. Several 
studies report that decreased ventilation is a significant risk factor for AMS2,3,4. Further 
evidence for this theory lies in the success of acetazolamide, a pharmaceutical carbonic 
anhydrase inhibitor, in preventing AMS symptoms. It has been shown that acetazolamide 
increases ventilation, although the mechanism for this action remains uncertain5.   
The existence of pulmonary and cerebral edemas, or swelling caused by excess fluid in 
the lungs and brain, respectively, in response to altitude has researchers examining fluid 
balance as a potential mechanism for AMS6,7. As previously mentioned, the compensatory 
mechanism for a respiratory-induced alkalosis is kidney-mediated excretion of bicarbonate 
in the urine. It is possible that retention of urine and bicarbonate, and the resulting alkalosis 
may have a cyclical effect on HVR by dampening its response6.  
AMS generally occurs above 2500m, when ascent rate exceeds an individual’s ability 
to acclimatize. It is characterized by headache and at least one other symptom, including 
gastrointestinal discomfort, fatigue, dizziness, or difficulty sleeping. It is the least severe, but 
most common, of the illnesses associated with altitude-related hypoxia, and frequently 
afflicts otherwise healthy people. According to one study conducted in Colorado, AMS affects 
25% of the general population that travel to moderate altitudes8. AMS is typically self-
limiting and not life-threatening, but it can affect quality of experience and decrease 
productivity9. Studies have shown that the AMS symptoms generally subside after several 
days of exposure, and that this acclimatization can have protective effects for future ascents 
for as long as 21 days later10. The most effective treatment for AMS is acclimatization or 
descent. Although a definitive link between AMS and the more severe illnesses of HACE and 
HAPE has yet to be found, continued rapid ascent increases risk of these potentially life-
threatening conditions11. 
Individual susceptibility to AMS and other altitude illnesses varies greatly, and the 
reasons for this are not well understood. However, there are known risk factors, including 
history of altitude illness, original residence below 900m, and certain preexisting 
cardiopulmonary conditions. Ascent rate and time at altitude are major contributing factors 
to an individual’s susceptibility. Older people (age 50 and above) are less prone than younger 
individuals12. Exercise at altitude is known to exacerbate symptoms13. As with most things, 
the variability in susceptibility is likely to due complex interactions between individual 
genetic factors and the environment, and relates to a person’s own ability to acclimatize. 
Multiple studies have attempted to create a risk prediction score based on relevant variables 
by compiling self-reported data. Reviews have been conducted for rate of ascent14 and 
preventive drug use15,16, but none so far have examined the relationship between sex and 
incidence of AMS.  
Physiological Rationale  
Because of the respiratory stimulant nature of the female sex hormone progesterone, 
it is hypothesized that females will have a lesser incidence of AMS. Two studies have shown 
that full-term pregnancy, a period of higher levels of circulating progesterone, increases 
resting ventilation and hypoxic and hypercapnic ventilatory responses17,18. A follow-up study 
examined the specific effects of female sex hormones and metabolic rate on HVR in 
postmenopausal women, and found that progestin-only and combined progestin and 
estrogen accounted for 50% of the increase in HVR19. Pre-travel clinics routinely discourage 
women from taking oral contraceptives (OC) while traveling at altitude, because they reduce 
the amount of circulating progesterone. In one study20, 85% of OC users experienced AMS 
symptoms compared to 51% of non-OC users (p=0.03) Furthermore, OC use was found to 
negate the preventive effects of acetazolamide use. This evidence supports the idea that the 
respiratory effects of progesterone might cause females to have a lesser incidence of AMS. 
These effects may be dependent on day of menstrual-cycle, as the levels of progesterone vary 
throughout the different phases of the cycle.  
 Methods  
 Studies Included 
MOOSE (Meta-analysis of Observational Studies in Epidemiology) guidelines were 
used for this systematic review and meta-analysis21. Search began in August 2014 using the 
PubMed database. Keywords included Acute Mountain Sickness, Risk or Prediction, and 
Gender or Sex. Titles and abstracts were searched for relevant variables, and initial 
eliminations were made at this point. Eligible studies for the review met the following 
criteria: 1) dependent variable was incidence of acute mountain sickness; 2) contained both 
male and female subjects; 3) sample size of at least 100 people; 4) reported effect size in 
odds ratios including 95% confidence intervals, or data that could be used to calculate odds 
ratios and confidence intervals; 5) used self-reported symptom questionnaires such as the 
Lake Louise Scoring System, Hackett’s Score, or the Environmental Symptoms Questionnaire 
III (as opposed to clinical assessment, see Appendix); 6) minimum altitude of study was 
2500m (cutoff for AMS), while maximum was 5500m (cutoff for ‘extreme altitude’)12; 7) 
must be able to be accessed for free through University of Colorado. Figure 1 depicts the 
method of locating eligible studies.  
If article could not be accessed free-of-charge through the database or the University 
of Colorado Library, authors were contacted by the given email. If no response was received 
by 1 February 2015, the article was excluded from the study. Relevant cited studies within 
articles were included if they met the inclusion criteria and no follow-up study was found. All 
articles used were published in English (one non-English study was not included because it 
did not meet the inclusion criteria).  
 
 
 
 
 
 
 
 
 
 
 
 
 
1481 results for “Acute Mountain 
Sickness” on PubMed database 
+"risk" yielded 238 
results 
+"gender" yielded 56 
results 
+"sex" yielded 44 
results 
+"prediction" yielded 
19 results 
Titles of 357 articles were assessed 
for relevance 
273 articles were excluded  
84 articles were assessed for the 
inclusion criteria 
12 articles and 18 relevant study 
populations were included in this 
review 
Figure 1. Flowchart 
describing method of 
finding eligible studies.  
Assessment of Acute Mountain Sickness 
Examples of the most common symptom quantification methods, including the Lake 
Louise Scoring System and Hackett’s Score, are included in the Appendix. The Environmental 
Symptoms Questionnaire Version III (ESQ-III) is the most burdensome to complete, and was 
developed to evaluate symptoms of military personnel when working in extreme conditions. 
It is not included in the Appendix, but it involves responding to 67 items and using item 
weight and an established divisor to determine factor score. ESQ-III can be used to assess 
respiratory AMS (AMS-R) and cerebral AMS (AMS-C)22. A shortened, online version of the 
ESQ-III has been developed and shown to be effective23. Hackett’s Score assesses symptoms 
both through a questionnaire and a physical examination by an experienced investigator24. 
The Lake Louise Scoring System was most favored by studies in this analysis. Its diagnostic 
criteria for AMS include a rise in altitude in the last 4 days, presence of a headache and at 
least one other symptom, a score of 3 or higher on the questionnaire. Lake Louise criteria for 
AMS, HACE and HAPE are also included in the Appendix. Comparisons of each method have 
yielded mixed results25,26, but in general, these three are accepted as the most relevant 
methods of assessing AMS symptoms.  
Data Analysis 
Table 1 shows relevant information for the studies analyzed. A few studies reported 
no significant relationship between sex and incidence of AMS27, or did not include usable 
data that showed this result28, or female sex was removed from the study entirely29. When 
their sample size is taken into consideration, these studies would have had a modest impact 
on the summary estimate, and so were excluded from the analysis. If effect size was not 
reported as an odds ratio, as in five of the studies8,26,36,37,48, this was calculated using a 2x2  
 Table 1.   Characteristics of Studies Assessing Sex and Risk of AMS 
Study  Population Altitude 
of Study 
Mean Age 
± SD 
Number 
of 
Subjects 
(Female) 
Effect Size Criteria Covariates 
Canouï-
Poitrine, et 
al., 20142 
Sea level 
subjects with or 
without 
previous 
experience 
>4000m 45.8 ± 13.5 
(with) 
42.6 ± 15.1 
(without) 
537 (164) 
(with) 
480 (214) 
(without) 
OR Hackett’s History of SHAI, rate of ascent, 
history of migraine, location, 
age, sex, activity level, 
ventilatory and cardiac 
responses 
McDevitt, et 
al., 201430 
English-
speaking 
subjects 
5400m 35 ± 12 332 (169) OR Lake 
Louise, 
ESQ-III 
Age, smoking status , BMI, 
AMS awareness 
Santantonio, 
et al., 201431 
Adults with 
pre-travel 
counseling 
>3500m 37 ± 16 162 (84) OR Hackett’s Sex, age, BMI, data about 
ascent, trip organized by 
travel agency, medical history, 
and previous experience at 
high-altitude 
Beidleman, et 
al., 201332 
Unacclimatized 
men and 
women 
Various 23.8 ± 5.4 308 (68) OR ESQ-III Altitude, time at altitude, 
activity level, age, body mass 
index, race, sex, and smoking 
status 
Richalet, et 
al., 201233 
Altitude 
visitors using 
or not using 
acetazolamide 
>3500m 42.6 ± 12.8 
(ACZ) 
45.3 ± 14.1 
(No ACZ) 
409 (n/a) 
(ACZ) 
917 (n/a) 
(No ACZ) 
OR Hackett’s Ascent rate, history of 
migraine, ventilatory response 
to exercise at hypoxia, 
desaturation during exercise 
at hypoxia 
Croughs, et 
al., 201134 
Travelers who 
consulted a 
pre-travel clinic 
>2500m, 
mean: 
3950m 
median: 
36, range: 
17-76 
744 (381) OR Lake 
Louise 
Previous AMS, age, gender 
maximum overnight altitude, 
number of acclimatization 
nights, ascent rate 
Bansyat, et 
al., 201035 
Nepali pilgrims 4300m 33 ± 14 228 (62) OR Lake 
Louise 
Age, sex, altitude 
acetazolamide use, alcohol 
during trip, smoking status,  
Jackson, et al., 
201036 
Trekkers on Mt. 
Kilimanjaro 
4370m 31 range: 
18-71 
189 (68) Raw data 
(OR was 
calculated) 
Lake 
Louise 
Ascent rate, acetazolamide 
use, rest day at 3700m, 
gastroenteritis, respiratory 
illness 
Karinen, et 
al., 200828 
Finnish 
trekkers on Mt. 
Kilimanjaro 
Various 51 ± 10 112 (58) Raw data 
(OR was 
calculated) 
Lake 
Louise 
Age, BMI, smoking status, 
altitude experience, 
acetazolamide use; respirator, 
cardiovascular and/or 
metabolic disease 
Ziaee, et al., 
200337 
Iranian 
trekkers 
2900m, 
4200m 
N/A 459 (148) Raw data 
(OR was 
calculated) 
Lake 
Louise 
Sex, age, height, weight, 
smoking status, weight of 
knapsack, time spent in 
shelter at 4200m 
Honigman, et 
al., 19938 
General tourist 
population 
1920m-
3000m 
43.8 ± 11.8 3140 
(981) 
Raw data 
(OR was 
calculated) 
Custom 
Score 
Residence <3000m, previous 
AMS symptoms, age <60 years, 
previous lung disease, poor or 
average physical condition 
Kayser, et al., 
199138 
Western 
trekkers in 
Nepal 
5400m Men: 30.6 
± 7.6 
Women: 
30.1 ± 8.5  
353 (160) Raw data 
(OR was 
calculated) 
ESQ-III Age, previous altitude 
experience, rate of ascent, 
smoking status, pre-trek 
training, oral contraceptives, 
number of trekkers in party, 
method of organization 
contingency table39 and confidence intervals were generated using the calculated standard 
errors. For one study32, incidence was found to be higher in men, so this odds ratio was 
inverted to obtain the female odds. Odds ratios with confidence intervals were compiled and 
a forest plot was created. Using the R meta package, fixed effect and random effects summary 
odds ratios were calculated, as well as test of heterogeneity (Q value).  
Because each of the studies has been conducted by a different set of researchers, and 
the idea is to be able to generalize the effects to a wider population, a random effects model 
computation is more appropriate for this meta-analysis. A fixed effects model assumes the 
only variation between studies occurs by chance or error because the studies are 
functionally identical. In this meta-analysis, a fixed effect model would provide a summary 
estimate that overemphasizes the relative weight of each study according to sample size. The 
summary estimate in a random effects model computation is the mean of a distribution of 
effect sizes, which better represents the variation between the studies in this analysis. The 
difference between a fixed effect model and a random effects model can be seen in the 
standard error equations for the summary estimate for each model. For simplicity, these 
equations assume identical standard deviation and sample size for all studies. Note: σ = 
standard deviation, k = number of one-group studies, n = sample size of each study, and τ = 
variance.  
Fixed Effect Model     
    	 
  
Random Effects Model 
    	 
   

	   
The standard error for a fixed effect model depends only on within-study variance. 
Standard error will approach zero when sample size is infinitely large. On the other hand, the 
random effects model equation has additional term, which represents between-study 
variance. Standard error in this case will only approach zero if the number of studies is 
infinitely large. For these reasons, the confidence intervals of the random effects model are 
usually wider than those of the fixed effect model. 
The test of heterogeneity (Q value) assesses the variation between studies, and 
whether this variation is statistically significant or not. A Q that is greater than the degrees of 
freedom, coupled with a p value less than 0.05 (sometimes 0.10 is used), suggests significant 
heterogeneity. It is expected that random effects model computations will have greater 
heterogeneity than fixed effect model computations40.  
Results 
 A total of twelve studies, with 18 separate and relevant study groups, were included 
in this analysis. Figure 2 shows the organization of the data about two reference lines, one 
where the value of 1 crosses the x-axis (dotted), and one that goes through the random 
effects summary odds ratio (solid). The increasing weight of each study was depicted by 
increasingly darker shades of blue. Studies were listed from oldest published to newest, to 
show the progression of results as time went on. A consolidation around the summary 
estimate can be seen in the studies published later than 2012, a promising trend.  
   
 Study         Relative Odds (95% Confidence Interval) 
1.66 (1.07-2.58) 
1.25 (1.06-1.49) 
0.81 (0.55-1.21) 
1.33 (0.57-3.14) 
0.73 (0.36-1.47) 
4.34 (1.83-10.7) 
1.61 (1.13-2.31) 
1.55 (1.01-2.37) 
1.45 (0.86-2.45) 
0.61 (0.31-1.19) 
2.28 (1.19-4.39) 
1.58 (0.88-2.84) 
1.39 (1.26-1.55) 
1.73 (1.04-2.88) 
1.73 (0.94-3.18) 
1.51 (0.90-2.52) 
1.38 (0.75-2.54) 
1.60 (0.96-2.67) 
2.07 (1.05-4.05) 
1.45 (1.25-1.68) 
Figure 2. Individual odds ratios and summary 
estimates of the association between female 
sex and incidence of AMS. 
The fixed effect summary estimate was 1.394 (95% CI = 1.258-1.546) and the random 
effects summary estimate was 1.484 (95% CI = 1.248-1.680), both with p-values of less than 
0.0001. However, as mentioned before, the random effects value is most relevant to this 
study. This indicates highly significant results, and an association between female sex and 
incidence of AMS. Statistical heterogeneity was assessed, and a Q value of 27.19 was found 
(df=17). However, the p-value for heterogeneity was 0.055, which does not meet the cut-off 
for significance, but does suggest moderate variation between studies, and reiterates the 
appropriateness of analyzing the random effects model summary estimate.  
 Three of the studies contained multiple subgroups within the study population 2,30,33. 
Canouï-Poitrine, et al., examined groups with and without previous experience, and within 
those groups, compared how clinical versus physio-clinical variables predicted risk of AMS. 
This study found that in females with previous experience, clinical variables were more 
predictive, whereas in females without previous experience, physio-clinical variables were 
more predictive of risk. The purpose was to develop an accurate scoring system based on 
clinical, physiological and environmental factors. Richalet, et al., only found a significant 
relationship between sex and incidence of AMS in females that did not take acetazolamide as 
a preventive measure. Acetazolamide use, perhaps, “levels the playing field” among 
individuals. McDevitt et al. separated groups according to their scores on the various 
questionnaires. Females that completed the ESQ-III showed greater odds of AMS than 
females that completed the Lake Louise Scoring System, which shows the variation between 
the diagnostic questionnaires that serves as a limitation for this meta-analysis.   
Other studies included in the meta-analysis showed interesting findings. Santantonio, 
et al., found female sex to be the most powerful predictor of AMS31. Basnyat, et al., reported 
an unusually high, but highly significant, odds ratio for females (4.340, 95% CI = 1.830-10.68, 
p=.0001)35. This study also found a higher incidence of HACE and HAPE for females, which 
has not been the trend for other studies32,44,45. It is an especially wide confidence interval, 
which weakens the result. However, the study reported a high incidence overall of AMS 
(68%) and noted that they did not control for dehydration, which could have led to an 
overestimation of AMS symptoms. Also, the ascent was considered very rapid compared to 
most expeditions, which could have exacerbated AMS symptoms. Beidleman, et al., Jackson et 
al. and Ziaee et al., all reported higher incidence of AMS in males, though their results were 
not statistically significant. Beidleman, et al., on the other hand, did report significantly 
higher severity of AMS in males than females, a result discussed later in this study. Karinen, 
et al., noted that females are more likely to descend at presentation of AMS symptoms, which 
could imply that females experience more debilitating symptoms of AMS, or that females are 
less likely to push their own physical limits. 
Discussion 
 This review suggests there is a relationship between sex and incidence of AMS, with 
greater incidence in females. This is contrary to the hypothesis, but highly unlikely due to 
chance alone (p<0.0001). In regards to mechanisms for this result, one study included in the 
review30 asked whether or not women tend to over-report symptoms. McDevitt et al. cited a 
study conducted in the U.K. that found no significant differences between men and women in 
their initial reporting of conditions31.  
The body responds to hypoxic environments in a number of ways; each of these 
responses presents a potential mechanism to explain why females tend to have a higher 
incidence of AMS. The time frame for each of these responses varies considerably, and some 
responses may not be as applicable to AMS, which occurs within hours of ascent to high 
altitude. First to occur, as mentioned previously, is the body’s hypoxic ventilatory response 
(HVR), which acts to increase ventilation and pO2. As discussed later, several studies have 
found that female sex hormones increase HVR, so this is not likely a mechanism by which 
females exhibit a higher incidence of AMS. 
  Second, the renal system responds to hypoxia by initiating diuresis and removal of 
bicarbonate1. In one study, those that eventually developed severe AMS displayed water 
retention within the first 3 hours of altitude exposure. Healthy subjects in the same study, by 
contrast, exhibited mild diuresis, or the excretion of urine7. The study surmises that this fast-
acting effect is due to an early increase in anti-diuretic hormone (ADH), a hormone 
responsible for water reabsorption by the kidneys. Estrogens have been shown to lower the 
threshold for ADH, increasing fluid retention41. This provides a potential mechanism for the 
results of this study. Furthermore, Hackett finds that fluid retention could be a related to a 
failure of the HVR, and a cause for AMS symptoms6. 
Third, the body exhibits a hematological response at altitude, a response often 
exploited by athletes training for endurance activities. Erythropoeitin (EPO) concentrations 
spike within hours of ascent, which stimulate a gradual increase in hemoglobin over the 
course of days to weeks at altitude. This response helps maintain oxygen delivery to tissues 
in hypoxemia1. Testosterone is known to be an erythropoetic hormone42. It is possible that 
testosterone, a predominantly male sex hormone, gives males an advantage at altitude by 
increasing EPO levels. Perhaps EPO helps to initiate fluid loss that correlates with avoidance 
of AMS symptoms.  
While the hypothesis was rejected, there may be hope for the idea that females are 
better equipped for high-altitude conditions. One study, noted previously, showed higher 
severity, as opposed to incidence, of AMS in males compared to females32. The females in the 
study, all premenopausal, demonstrated 29% lower severity (p= 0.05) than men, which is 
consistent with one other study43. These findings align with previous research, conducted at 
Colorado ski resorts, that suggests a greater susceptibility of males than females to HAPE, a 
more severe altitude illness44,45. These studies surmise that this outcome could be due to 
increased ventilation in females, mediated by the female sex hormone, progesterone, a 
known respiratory stimulant19.   
After conducting this meta-analysis and becoming more familiar with the topic, it 
became clear that the studies included lacked crucial information to evaluate the hypothesis. 
None of the studies provided information about circulating progesterone levels in females, 
for example by reporting day of menstrual cycle, or oral contraceptive use. Only the mean 
age of female subjects can be used to guess whether or not the majority of subjects were pre- 
or post-menopausal, which not all studies provided. That progesterone levels vary 
significantly throughout the menstrual cycle and reproductive stage could be a confounding 
variable for this meta-analysis. Perhaps a majority of the females in were in the follicular 
phase of their cycle, or were post-menopausal, and thus had lower progesterone levels. 
However, if the inclusion criteria were updated to include female-specific information, there 
would not have been enough studies to conduct the analysis in the first place. These gaps in 
information are common in meta-analyses and limit the power of the conclusions than can be 
drawn.  
Limitations  
This study was limited in its scope due to the observational nature of the data used. As 
is possible with any meta-analysis, there were inherent differences in the conditions under 
which the data was obtained in each study. For example, each study was conducted at 
slightly different altitudes, in different geographic locations, with subjects of different 
backgrounds and levels of expertise, and so forth. Each study adjusted data for its own 
important factors such as age, smoking status and previous experience, but these covariates 
were not consistent across all studies. Additionally, the subjective nature of diagnosing AMS 
is a limit to any study examining this illness. Symptoms, and thus incidence of AMS, are self-
reported by subjects using questionnaires, rather than measured or obtained by more 
objective means. Much of the data is dependent on survey responses, which could lead to 
selection bias. Additionally, this study was limited to analyzing articles that could be 
accessed for free through the University of Colorado, or by other reasonable means. Finally, 
as mentioned earlier, information about progesterone levels was not included for the females 
in the studies used for meta-analysis.  
Recommendations for Further Research  
No causal relationship can be determined from this study because of its observational 
and non-interventional nature. Therefore, it would be beneficial to conduct a case-control 
study to verify a causal association between female sex and higher incidence of AMS. 
Additionally, research is needed to assess the link between the sex hormones and the 
physiological response to altitude, and to determine the mechanisms for associations that 
have already been established. This includes, but is not limited to, sex hormone and EPO role 
in the ventilatory response and fluid retention. Careful attention should be paid to female OC 
use and phase of menstrual cycle.  
 
 
Conclusions 
 According to this study, there is a relationship between female sex and incidence of 
Acute Mountain Sickness, which is contrary to the hypothesis. There is a multitude of factors 
contributing to a person’s development of altitude illnesses, and further research is needed 
in many aspects of this field.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
                                                        
1 Luks AM. Physiology in Medicine: A physiologic approach to prevention and treatment of 
acute high-altitude illnesses. J Appl Physiol (1985). 2015 Mar 1;118(5):509-519. doi: 
10.1152/japplphysiol.00955.2014. Epub 2014 Dec 24. Review. PubMed PMID: 25539941. 
 
2 Canouï-Poitrine F, Veerabudun K, Larmignat P, Letournel M, Bastuji-Garin S, Richalet JP. 
Risk prediction score for severe high altitude illness: a cohort study. PLoS One. 2014 Jul 
28;9(7):e100642. doi: 10.1371/journal.pone.0100642. eCollection 2014. PubMed PMID: 
25068815; PubMed Central PMCID: PMC4113313. 
 
3 Moore LG, Harrison GL, McCullough RE, McCullough RG, Micco AJ, Tucker A, Weil JV, Reeves 
JT. Low acute hypoxic ventilatory response and hypoxic depression in acute altitude sickness. 
J Appl Physiol 60: 1407–1412, 1986. 
 
4 Richalet JP, Larmignat P, Poitrine E, Letournel M, Canouï-Poitrine F. Physiological risk 
factors for severe high-altitude illness: a prospective cohort study. Am J Respir Crit Care Med. 
2012 Jan 15;185(2):192-8. doi: 10.1164/rccm.201108-1396OC. Epub 2011 Oct 27. PubMed 
PMID: 22071330. 
 
5 Leaf DE, Goldfarb DS. Mechanisms of action of acetazolamide in the prophylaxis and 
treatment of acute mountain sickness. J Appl Physiol (1985). 2007 Apr;102(4):1313-22. 
Epub 2006 Oct 5. Review. PubMed PMID: 17023566. 
 
6 Hackett PH, Rennie D, Hofmeister SE, Grover RF, Grover EB, Reeves JT. Fluid retention and 
relative hypoventilation in acute mountain sickness. Respiration. 1982;43(5):321-9. PubMed 
PMID: 6815746. 
 
7 Loeppky JA, Icenogle MV, Maes D, Riboni K, Hinghofer-Szalkay H, Roach RC. Early fluid 
retention and severe acute mountain sickness. J Appl Physiol (1985). 2005 Feb;98(2):591-7. 
Epub 2004 Oct 22. PubMed PMID: 15501929. 
 
8 Honigman B, Theis MK, Koziol-McLain J, Roach R, Yip R, Houston C, Moore LG, Pearce P. 
Acute mountain sickness in a general tourist population at moderate altitudes. Ann Intern 
Med. 1993 Apr 15;118(8):587-92. Erratum in: Ann Intern Med 1994 Apr 15;120(8):698. 
PubMed PMID: 8452324. 
 
9 Song H, Ke T, Luo WJ, Chen JY. Non-high altitude methods for rapid screening of 
susceptibility to acute mountain sickness. BMC Public Health. 2013 Sep 30;13:902. doi: 
10.1186/1471-2458-13-902. PubMed PMID: 24079477; PubMed Central PMCID: 
PMC3852617. 
 
 
 
 
 
                                                                                                                                                                                      
10 Subudhi AW, Bourdillon N, Bucher J, Davis C, Elliott JE, Eutermoster M, Evero O, Fan JL, 
Jameson-Van Houten S, Julian CG, Kark J, Kark S, Kayser B, Kern JP, Kim SE, Lathan C, Laurie 
SS, Lovering AT, Paterson R, Polaner DM, Ryan BJ, Spira JL, Tsao JW, Wachsmuth NB, Roach 
RC. AltitudeOmics: the integrative physiology of human acclimatization to hypobaric hypoxia 
and its retention upon reascent. PLoS One. 2014 Mar 21;9(3):e92191. doi: 
10.1371/journal.pone.0092191. eCollection 2014. PubMed PMID: 24658407; PubMed 
Central PMCID: PMC3962396. 
 
11 Hackett PH, Roach RC. High-altitude illness. N Engl J Med. 2001 Jul 12;345(2):107-14. 
Review. PubMed PMID: 11450659. 
 
12 Taylor AT. High-altitude illnesses: physiology, risk factors, prevention, and treatment. 
Rambam Maimonides Med J. 2011 Jan 31;2(1):e0022. doi: 10.5041/RMMJ.10022. Print 2011 
Jan. PubMed PMID: 23908794; PubMed Central PMCID: PMC3678789. 
 
13 Roach RC, Maes D, Sandoval D, Robergs RA, Icenogle M, Hinghofer-Szalkay H, Lium D, 
Loeppky JA. Exercise exacerbates acute mountain sickness at simulated high altitude. J Appl 
Physiol (1985). 2000 Feb;88(2):581-5. PubMed PMID: 10658026. 
 
14 Hsu TY, Weng YM, Chiu YH, Li WC, Chen PY, Wang SH, Huang KF, Kao WF, Chiu TF, Chen JC. 
Rate of ascent and acute mountain sickness at high altitude. Clin J Sport Med. 2015 
Mar;25(2):95-104. doi: 10.1097/JSM.0000000000000098. PubMed PMID: 24751723. 
 
15 DeLellis SM, Anderson SE, Lynch JH, Kratz K. Acute mountain sickness prophylaxis: a high-
altitude perspective. Curr Sports Med Rep. 2013 Mar-Apr;12(2):110-4. doi: 
10.1249/JSR.0b013e3182874d0f. Review. PubMed PMID: 23478562. 
 
16 Ritchie ND, Baggott AV, Andrew Todd WT. Acetazolamide for the prevention of acute 
mountain sickness--a systematic review and meta-analysis. J Travel Med. 2012 Sep-
Oct;19(5):298-307. doi: 10.1111/j.1708-8305.2012.00629.x. Epub 2012 Jul 30. Review. 
PubMed PMID: 22943270. 
 
17 Regensteiner JG, Woodard WD, Hagerman DD, Weil JV, Pickett CK, Bender PR, Moore LG. 
Combined effects of female hormones and metabolic rate on ventilatory drives in women. J 
Appl Physiol (1985). 1989 Feb;66(2):808-13. PubMed PMID: 2540141. 
 
18 Pernoll ML, Metcalfe J, Kovach PA, Wachtel R, Dunham MJ. Ventilation during rest and 
exercise in pregnancy and postpartum. Respir Physiol. 1975 Dec;25(3):295-310. PubMed 
PMID: 1226465. 
 
19 Moore LG, McCullough RE, Weil JV. Increased HVR in pregnancy: relationship to hormonal 
and metabolic changes. J Appl Physiol (1985). 1987 Jan;62(1):158-63. PubMed PMID: 
3104285. 
 
20 Harrison MF, Anderson P, Miller A, O'Malley K, Richert M, Johnson J, Johnson BD. Oral 
contraceptive use and acute mountain sickness in South Pole workers. Aviat Space Environ 
Med. 2013 Nov;84(11):1166-71. PubMed PMID: 24279230. 
                                                                                                                                                                                      
 
21 https://www.editorialmanager.com/jognn/account/MOOSE.pdf. Accessed 9 Mar 2015. 
 
22 www.dtic.mil/cgi-bin/GetTRDoc?AD=ADA264127. Accessed 10 Mar 2015. 
 
23 Beidleman BA, Muza SR, Fulco CS, Rock PB, Cymerman A. Validation of a shortened 
electronic version of the environmental symptoms questionnaire. High Alt Med Biol. 2007 
Fall;8(3):192-9. PubMed PMID: 17824819. 
 
24 Roeggla G, Roeggla M, Podolsky A, Wagner A, Laggner AN. How can acute mountain 
sickness be quantified at moderate altitude? J R Soc Med. 1996 Mar;89(3):141-3. PubMed 
PMID: 8683517; PubMed Central PMCID: PMC1295697. 
 
25 Savourey G, Guinet A, Besnard Y, Garcia N, Hanniquet AM, Bittel J. Evaluation of the Lake 
Louise acute mountain sickness scoring system in a hypobaric chamber. Aviat Space Environ 
Med. 1995 Oct;66(10):963-7. PubMed PMID: 8526833. 
 
26 Dellasanta P, Gaillard S, Loutan L, Kayser B. Comparing questionnaires for the assessment 
of acute mountain sickness. High Alt Med Biol. 2007 Fall;8(3):184-91. PubMed PMID: 
17824818. 
 
27 Vardy J, Vardy J, Judge K. Acute mountain sickness and ascent rates in trekkers above 2500 
m in the Nepali Himalaya. Aviat Space Environ Med. 2006 Jul;77(7):742-4. PubMed PMID: 
16856361. 
 
28 Karinen H, Peltonen J, Tikkanen H. Prevalence of acute mountain sickness among Finnish 
trekkers on Mount Kilimanjaro, Tanzania: an observational study. High Alt Med Biol. 2008 
Winter;9(4):301-6. doi: 10.1089/ham.2008.1008. PubMed PMID: 19115914. 
 
29 Salazar H, Swanson J, Mozo K, White AC Jr, Cabada MM. Acute mountain sickness impact 
among travelers to Cusco, Peru. J Travel Med. 2012 Jul;19(4):220-5. doi: 10.1111/j.1708-
8305.2012.00606.x. Epub 2012 Apr 19. PubMed PMID: 22776382. 
 
30 McDevitt M, McIntosh SE, Rodway G, Peelay J, Adams DL, Kayser B. Risk determinants of 
acute mountain sickness in trekkers in the Nepali Himalaya: a 24-year follow-up. Wilderness 
Environ Med. 2014 Jun;25(2):152-9. doi: 10.1016/j.wem.2013.12.027. PubMed PMID: 
24864065. 
 
31 Santantonio M, Chapplain JM, Tattevin P, Leroy H, Mener E, Gangneux JP, Michelet C, Revest 
M. Prevalence of and risk factors for acute mountain sickness among a cohort of high-altitude 
travellers who received pre-travel counselling. Travel Med Infect Dis. 2014 Sep-
Oct;12(5):534-40. doi: 10.1016/j.tmaid.2014.08.004. Epub 2014 Sep 2. PubMed PMID: 
25224954. 
 
32 Beidleman BA, Tighiouart H, Schmid CH, Fulco CS, Muza SR. Predictive models of acute 
mountain sickness after rapid ascent to various altitudes. Med Sci Sports Exerc. 2013 
Apr;45(4):792-800. doi: 10.1249/MSS.0b013e31827989ec. PubMed PMID: 23135373. 
                                                                                                                                                                                      
 
33 Richalet JP, Larmignat P, Poitrine E, Letournel M, Canouï-Poitrine F. Physiological risk 
factors for severe high-altitude illness: a prospective cohort study. Am J Respir Crit Care Med. 
2012 Jan 15;185(2):192-8. doi: 10.1164/rccm.201108-1396OC. Epub 2011 Oct 27. PubMed 
PMID: 22071330. 
 
34 Croughs M, Van Gompel A, Van den Ende J. Acute mountain sickness in travelers who 
consulted a pre-travel clinic. J Travel Med. 2011 Sep-Oct;18(5):337-43. doi: 10.1111/j.1708-
8305.2011.00537.x. Epub 2011 Jun 14. PubMed PMID: 21896098. 
 
35 Basnyat B, Subedi D, Sleggs J, Lemaster J, Bhasyal G, Aryal B, Subedi N. Disoriented and 
ataxic pilgrims: an epidemiological study of acute mountain sickness and high-altitude 
cerebral edema at a sacred lake at 4300 m in the Nepal Himalayas. Wilderness Environ Med. 
2000 Summer;11(2):89-93. PubMed PMID: 10921358. 
 
36 Jackson SJ, Varley J, Sellers C, Josephs K, Codrington L, Duke G, Njelekela MA, Drummond G, 
Sutherland AI, Thompson AA, Baillie JK. Incidence and predictors of acute mountain sickness 
among trekkers on Mount Kilimanjaro. High Alt Med Biol. 2010 Fall;11(3):217-22. doi: 
10.1089/ham.2010.1003. PubMed PMID: 20919888. 
 
37 Ziaee V, Yunesian M, Ahmadinejad Z, Halabchi F, Kordi R, Alizadeh R, Afsharjoo HR. Acute 
mountain sickness in Iranian trekkers around Mount Damavand (5671 m) in Iran. 
Wilderness Environ Med. 2003 Winter;14(4):214-9. PubMed PMID: 14719853. 
 
38 Kayser, B. Acute mountain sickness in western tourists around the Thorong Pass (5400 m) 
in Nepal. J Wilderness Med. 1991; 2: 110–117 
 
39 http://sphweb.bumc.bu.edu/otlt/MPH-Modules/BS/BS704-EP713_Confounding-
EM/BS704-EP713_Confounding-EM7.html. Accessed 3 Mar 2015.  
 
40 Borenstein, M., Hedges, L. V., Higgins, J. P. T. and Rothstein, H. R. (2009) References, in 
Introduction to Meta-Analysis, John Wiley & Sons, Ltd, Chichester, UK. 
doi: 10.1002/9780470743386.refs 
 
41 Stachenfeld NS, Silva C, Keefe DL, Kokoszka CA, Nadel ER. Effects of oral contraceptives on 
body fluid regulation. J Appl Physiol (1985). 1999 Sep;87(3):1016-25. PubMed PMID: 
10484572. 
 
42 Shahani S, Braga-Basaria M, Maggio M, Basaria S. Androgens and erythropoiesis: past and 
present. J Endocrinol Invest. 2009 Sep;32(8):704-16. doi: 10.3275/6149. Epub 2009 Apr 7. 
Review. PubMed PMID: 19494706. 
 
43 Hannon JP. Comparative altitude adaptability of young men and women. In: Folinsbee LJ, 
Wagner JA, Bergia JF, Drinkwater BL, Gliner JA, Bedi JF, editors. Environmental Stress. 
Individual Human Adaptations. New York: Academic Press; 1978. pp. 335–50 
 
                                                                                                                                                                                      
44 Hultgren HN, Honigman B, Theis K, Nicholas D. High-altitude pulmonary edema at a ski 
resort. West J Med. 1996 Mar;164(3):222-7. PubMed PMID: 8775933; PubMed Central 
PMCID: PMC1303414. 
 
45 Sophocles AM Jr. High-altitude pulmonary edema in Vail, Colorado, 1975-1982. West J Med. 
1986 May;144(5):569-73. PubMed PMID: 3716417; PubMed Central PMCID: PMC1306705. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                                      
Appendix  
 
Figure 3. Lake Louise Criteria for Altitude Illness  
Acute Mountain Sickness 
In the setting of a recent gain in altitude, the presence of headache and at least one of the 
following symptoms: 
• Gastrointestinal (anorexia, nausea or vomiting) 
• Fatigue or weakness 
• Dizziness or lightheadedness 
• Difficulty sleeping 
 
High Altitude Cerebral Edema 
Can be considered "end stage" or severe AMS. In the setting of a recent gain in altitude, either: 
• The presence of a change in mental status and/or ataxia in a person with AMS 
• Or, the present of both mental status changes and ataxia in a person without AMS 
 
High Altitude Pulmonary Edema 
In the setting of a recent gain in altitude, the presence of the following: 
 
  Symptoms: at least two of: 
    
• Dyspnea at rest 
• Cough 
• Weakness or decreased exercise performance 
• Chest tightness or congestion 
  Signs: at least two of: 
    
• Crackles or wheezing in at least one lung field 
• Central cyanosis 
• Tachypnea 
• Tachycardia 
 
 
 
 
http://www.high-altitude-medicine.com/AMS-LakeLouise.html, accessed 13 Mar 2015. 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                                      
Lake Louise Score (LLS) for the  
diagnosis of Acute Mountain Sickness (AMS) 
A diagnosis of AMS is based on: 
     1. A rise in altitude within the last 4 days 
     2. Presence of a headache 
PLUS 
     3. Presence of at least one other symptom 
     4. A total score of 3 or more from the questions below 
SELF-REPORT QUESTIONNAIRE 
Add together the individual scores for each symptoms to get the total score. 
Headache No headache 0  
Mild headache 1  
Moderate headache 2  
Severe headache, incapacitating 3  
 
Gastrointestinal symptoms None 0  
 Poor appetite or nausea 1  
 Moderate nausea &/or vomiting 2  
 Severe nausea &/or vomiting 3  
 
Fatigue &/or weakness Not tired or weak 0  
 Mild fatigue/weakness 1  
 Moderate fatigue/weakness 2  
 Sever fatigue/weakness 3  
 
Dizziness/lightheadedness Not dizzy 0  
 Mild dizziness 1  
 Moderate dizziness 2  
 Severe dizziness, incapacitating 3  
 
Difficulty sleeping Slept well as usual 0  
 Did not sleep well as usual 1  
 Woke many times, poor sleep 2  
 Could not sleep at all 3  
 TOTAL SCORE:   
Total score of: 
• 3 to 5 =  mild AMS 
• 6 or more = severe AMS 
Note: Do not ascend with AMS symptoms. Descend if symptoms are not improving or getting worse. Descend if 
symptoms of HACE or HAPE develop.  
http://www.high-altitude-medicine.com/AMS-LakeLouise.html, accessed 13 Mar 2015. 
                                                                                                                                                                                      
Table 2. Hackett Score for AMS34  
Symptoms Score 
Headache relieved after a first degree analgesica 1 
Nausea 1 
Loss of appetite 1 
Insomnia 1 
Dizziness, light-headedness 1 
Headache not relieved after a first degree analgesic (paracetamol, 
ibuprofen or acetylsalicylic acid) 
2 
Vomiting 2 
Dyspnoea at rest 3 
Unusual level of asthenia 3 
Oliguria 3 
Total /18 
 
Interpretation: 
Total = 1–3: slight acute mountain sickness (AMS). 
Total = 4–6: mild AMS. 
Total >6: severe AMS. 
 
 
